Suven Pharmaceuticals (BOM:543064) Debt-to-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Debt-to-Asset?

Suven Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹438 Mil. Suven Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹212 Mil. Suven Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ₹22,541 Mil. Suven Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.03.

Suven Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Suven Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Debt-to-Asset Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.16

0.10

0.05

0.04

0.03

Suven Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.04	-	0.02	-	0.03

Competitive Comparison of Suven Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suven Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Suven Pharmaceuticals's Debt-to-Asset falls into.

Suven Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Suven Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(437.608	+	212.356)	/	22540.865
	=	0.03

Suven Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(437.608	+	212.356)	/	22540.865
	=	0.03

Suven Pharmaceuticals (BOM:543064) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Suven Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals (BOM:543064) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Debt-to-Asset

Traded in Other Exchanges

SUVENPHAR:India

Address

3rd Floor, Road No. 5, Avenue 7, Banjara Hills, No. 8-2-334, SDE Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.

Suven Pharmaceuticals (BOM:543064) Headlines

No Headlines